Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTD4010 SAD in Healthy Volunteers
NCT02538848Phase 1Completed
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Oct 2015
- Primary completion
- Mar 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HTD4010 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by HighTide Therapeutics, Inc. Primary endpoint: Incidence, severity and causality of adverse events at 1 day. Started Oct 2015; status: completed.
02
Drugs
HTD4010
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02538848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538848.